Table 3

Baseline characteristics for the first 275 included patients

n139 (Arm 1)136 (Arm 2)
Age (year, mean (SD))62 (6.2)64 (6.2)
PSA (ng/mL, mean, (SD))5.1 (2.3)5.8 (2.3)
PSA-D (ng/mL/cc, mean (SD))0.11 (0.04)0.12 (0.04)
Clinical tumour stage (n (%))
 T1c109 (78)115 (85)
 T2a29 (21)21 (15)
 Unknown1 (1)0
Comorbidity (n (%))
 ASA 194 (68)84 (62)
 ASA 240 (29)52 (38)
 ASA 34 (3)0
 Unknown1 (1)0
Family history of PCA (n (%))
 Yes33 (24)38 (28)
 No102 (73)95 (70)
 Unknown4 (3)3 (2)
MRI technique (n (%))
 1.5 T20 (14)16 (12)
 3 T118 (85)116 (85)
 Unknown1 (1)4 (3)
MRI findings (n (%))
 PI-RADS 1–276 (55)55 (40)
 PI-RADS 3–563 (45)81 (60)
  • ASA, American Society of Anesthesiologists classification; PCA, prostate cancer; PI-RADS, Prostate Imaging Reporting and Data System; PSA, prostate-specific antigen; n, sample size.